Ventyx Biosciences, Inc. Logo

Ventyx Biosciences, Inc.

Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.

VTYX | US

Overview

Corporate Details

ISIN(s):
US92332V1070
LEI:
Country:
United States of America
Address:
12790 EL CAMINO REAL, SUITE 200, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. Leveraging expertise in medicinal chemistry, structural biology, and immunology, the company discovers and advances differentiated small molecule therapeutics for conditions with high unmet medical need. Its pipeline includes NLRP3 inhibitors VTX2735 (Phase 2 for recurrent pericarditis) and VTX3232 (Phase 2 for neurodegenerative and cardiometabolic diseases). The inflammatory bowel disease portfolio features S1P1R modulator tamuzimod and TYK2 inhibitor VTX958, both of which have completed Phase 2 clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ventyx Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ventyx Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ventyx Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.